Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Hepatitis

Free Subscription Articles published in J Hepatol Retrieve available abstracts of 211 articles: HTML format

Single Articles

August 2026
1. HARTL J, Weltzsch JP, Sebode M, Schramm C, et al
   Anti-TNF therapy in autoimmune hepatitis: We should move faster.
   J Hepatol. 2026 Aug 5:S0168-8278(26)02755-8. doi: 10.1016/j.jhep.2026.
   PubMed    
   
   
   July 2026
2. PAPATHEODORIDIS GV, Dalekos G, Idilman R, Sypsa V, et al
   Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort.
   J Hepatol. 2026 Jul 6:S0168-8278(26)02702-9. doi: 10.1016/j.jhep.2026.
   PubMed     Abstract available
   
   
   
3. BERG T, van Bommel F, Urban S
   When Biology Pushes Back: Lessons From HBsAg-Targeting Therapies in Hepatitis Delta.
   J Hepatol. 2026 Jul 4:S0168-8278(26)02704-2. doi: 10.1016/j.jhep.2026.
   PubMed    
   
   
   
4. MO W, Dong Y, Jia T, Zeng Y, et al
   Moving Too Fast? A Meta-Analysis Calls for Caution on TNF Inhibitors as First-Line Therapy for Autoimmune Hepatitis.
   J Hepatol. 2026 Jul 3:S0168-8278(26)02661-9. doi: 10.1016/j.jhep.2026.
   PubMed    
   
   
   June 2026
5. SOLOMON SS, Srikrishnan AK, McFall AM, Baishya J, et al
   A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.
   J Hepatol. 2026 Jun 30:S0168-8278(26)02683-8. doi: 10.1016/j.jhep.2026.
   PubMed     Abstract available
   
   
   
6. YU S, Yu J, Zhang W, Cheng L, et al
   Retraction notice to "Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation" [J Hepatol 61 (2014) 809-815].
   J Hepatol. 2026 Jun 12:S0168-8278(26)02588-2. doi: 10.1016/j.jhep.2026.
   PubMed    
   
   
   
7. LOUVET A, Ntandja Wandji LC, Mathurin P
   Updates in clinical science: Alcohol-related hepatitis.
   J Hepatol. 2026 Jun 10:S0168-8278(26)00219-9. doi: 10.1016/j.jhep.2026.
   PubMed     Abstract available
   
   
   
8. CECCATELLI BERTI C, Montali I, Doselli S, Farina B, et al
   Dysregulated transcription in core- and pol-specific CD8 T cells can be targeted by HDAC inhibition to improve T-cell function in chronic hepatitis B.
   J Hepatol. 2026 Jun 5:S0168-8278(26)02622-X. doi: 10.1016/j.jhep.2026.
   PubMed     Abstract available
   
   
   
9. FONDEVILA MF, Kreimeyer H, Hsu CL, Tamargo-Azpilicueta J, et al
   Macrophage-derived cathepsin B disrupts intestinal tight junctions through occludin degradation and promotes alcohol-associated liver disease.
   J Hepatol. 2026;84:1045-1061.
   PubMed     Abstract available
   
   
   May 2026
10. WEDEMEYER H, Gane E, Agarwal K, Fehmi Tabak O, et al
    siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.
    J Hepatol. 2026 May 15:S0168-8278(26)00282-5. doi: 10.1016/j.jhep.2026.
    PubMed     Abstract available
    
    
    
11. CLARKE ZA, Atif J, Wang X, Liu LY, et al
    A single-cell atlas of the woodchuck liver reveals cellular programs conserved in human HBV infection.
    J Hepatol. 2026;84:962-975.
    PubMed     Abstract available
    
    
    
12. CHENG X, Xia Y, Li C, Zhang M, et al
    A genome-wide siRNA screen identifies previously unknown proviral and antiviral host factors in HBV infection.
    J Hepatol. 2026;84:874-886.
    PubMed     Abstract available
    
    
    April 2026
13. FU X, Wang Y, Wang G
    Beyond steroid-dependent care: can TNF blockade evolve into a precision therapy for autoimmune hepatitis?
    J Hepatol. 2026 Apr 29:S0168-8278(26)00222-9. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    
14. HOIVIK ML, Tilg H
    Anti-TNF therapies in autoimmune hepatitis: promises and challenges.
    J Hepatol. 2026 Apr 29:S0168-8278(26)00214-X. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    
15. KINAST V, Desert R, Bartenschlager R, Baumert TF, et al
    Renewed momentum for HCV and HCC research.
    J Hepatol. 2026 Apr 22:S0168-8278(26)00188-1. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    
16. VAN MELKEBEKE L, Boesch M, Ostyn T, Huang W, et al
    Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis.
    J Hepatol. 2026 Apr 20:S0168-8278(26)00205-9. doi: 10.1016/j.jhep.2026.
    PubMed     Abstract available
    
    
    
17. WEDEMEYER H, Aleman S, Blank A, Andreone P, et al
    144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial.
    J Hepatol. 2026 Apr 9:S0168-8278(26)00201-1. doi: 10.1016/j.jhep.2026.
    PubMed     Abstract available
    
    
    
18. SONNEVELD MJ, Janssen HLA
    Individualising endpoints in chronic HBV treatment: HBsAg loss and beyond.
    J Hepatol. 2026;84:823-828.
    PubMed     Abstract available
    
    
    March 2026
19. DONGELMANS E, Hirode G, van B?mmel F, Jeng WJ, et al
    Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B - follow-up from the RETRACT-B cohort.
    J Hepatol. 2026 Mar 30:S0168-8278(26)00185-6. doi: 10.1016/j.jhep.2026.
    PubMed     Abstract available
    
    
    
20. XU Y, Weltzsch JP, Kilian C, Steglich B, et al
    Integrative omics and phase IIa clinical trial identify TNF as key node in autoimmune hepatitis.
    J Hepatol. 2026 Mar 19:S0168-8278(26)00120-0. doi: 10.1016/j.jhep.2026.
    PubMed     Abstract available
    
    
    
21. SONNEVELD MJ, Janssen HLA
    Is Partial Cure a Realistic Endpoint for Novel Hepatitis B Therapy? Reply to Chan et al.
    J Hepatol. 2026 Mar 11:S0168-8278(26)00134-0. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    
22. BATISTA MN, Bordignon J, Pamplona Mosimann AL, Bobrowski T, et al
    An immunocompetent murine model of virus-elicited liver fibrosis and hepatocellular carcinoma.
    J Hepatol. 2026 Mar 11:S0168-8278(26)00085-1. doi: 10.1016/j.jhep.2026.
    PubMed     Abstract available
    
    
    
23. STERN C, Loustaud-Ratti V, Yurdaydin C, Brancaccio G, et al
    Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program.
    J Hepatol. 2026;84:531-542.
    PubMed     Abstract available
    
    
    February 2026
24. TAK KY, Lee J, Jang JW, Lee SK, et al
    Incidence and Risk Stratification of Hepatitis B Reactivation in Patients Receiving Anti-CD38 Monoclonal Antibody Therapy.
    J Hepatol. 2026 Feb 13:S0168-8278(26)00067-X. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    
25. WANG J, Zhang S, Zhu C, Wu C, et al
    Discrepancies in Treatment Eligibility Across International Guidelines for Chronic Hepatitis B.
    J Hepatol. 2026 Feb 12:S0168-8278(26)00068-1. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    January 2026
26. SANDMANN L
    Tobevibart and elebsiran for the treatment of chronic hepatitis delta.
    J Hepatol. 2026 Jan 19:S0168-8278(25)02737-0. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
27. CHAN HLY, Wong VWS, Wong GLH
    Is Partial Cure a Realistic Endpoint for Novel Hepatitis B Therapy?
    J Hepatol. 2026 Jan 17:S0168-8278(26)00012-7. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    
28. BOUQUET J, Speer SD, Koenig A, Livingston CM, et al
    Single nucleotide polymorphisms in the bepirovirsen binding site have limited impact on treatment response in chronic hepatitis B.
    J Hepatol. 2026 Jan 14:S0168-8278(26)00008-5. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
29. VINCENZETTI L, Wong R, Marzi R, Guarino B, et al
    Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells.
    J Hepatol. 2026;84:62-73.
    PubMed     Abstract available
    
    
    December 2025
30. LE BERT N, Koffas A, Kumar R, Facchetti F, et al
    Rapid whole-blood immune profiling reveals heterogeneous HBV-specific T cell response patterns independent of clinical disease phases.
    J Hepatol. 2025;83:1292-1304.
    PubMed     Abstract available
    
    
    
31. CHAN LL, Chan AWH, Yip TCF, Wong GLH, et al
    Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era.
    J Hepatol. 2025;83:1328-1337.
    PubMed     Abstract available
    
    
    November 2025
32. LLIBRE JM, Boesecke C, Moon J, Lank PM, et al
    A phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C.
    J Hepatol. 2025 Nov 24:S0168-8278(25)02625-X. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
33. YU J, Chen X, Li H, Xu Z, et al
    Geographic disparities in hepatitis B vaccine coverage across Africa: Implications for targeted interventions and 2030 goals.
    J Hepatol. 2025 Nov 24:S0168-8278(25)02655-8. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
34. SANDMANN L
    The identification of interleukin-27 as one key player in restoring virus-specific T-cell dysfunction in chronic hepatitis B virus infection.
    J Hepatol. 2025 Nov 19:S0168-8278(25)02604-2. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
35. WANG J, Fan T, Zhu C, Wu C, et al
    Prevalence and Antiviral Treatment Rate in Chronic Hepatitis B Patients with a Family History of HCC.
    J Hepatol. 2025 Nov 14:S0168-8278(25)02621-2. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    October 2025
36. YUAN H, Zhao L, Yang G, Zhang S, et al
    HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responses.
    J Hepatol. 2025 Oct 16:S0168-8278(25)02556-5. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
37. POLAT M, Wahlin S, Efe C
    Can Autoimmune Hepatitis be diagnosed and treated without liver biopsy?
    J Hepatol. 2025 Oct 10:S0168-8278(25)02552-8. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
38. DINKELBORG K, Lhomme S, Gomer A
    Rat Hepatitis E Virus: An Emerging Challenge in Human Hepatitis.
    J Hepatol. 2025 Oct 3:S0168-8278(25)02515-2. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    September 2025
39. DALEKOS GN, Gatselis N, Tiniakos D
    EASL CPG: Liver biopsy cannot be skipped for the diagnosis of autoimmune hepatitis.
    J Hepatol. 2025 Sep 3:S0168-8278(25)02468-7. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    August 2025
40. HOFMANN M, Rehermann B
    T Cells in a Drop: Rapid T Cell Monitoring in Chronic Hepatitis B.
    J Hepatol. 2025 Aug 22:S0168-8278(25)02443-2. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    July 2025
41. SANDMANN L
    From HCV to HEV: Repurposing a nucleoside analogue for hepatitis E therapy.
    J Hepatol. 2025 Jul 31:S0168-8278(25)02322-0. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
42. HON-YIN LO K, Stanley Ho SF, Hon-Kiu Shun E, Wu S, et al
    Enhanced surveillance, subtyping, and host adaptation analysis reveal genotype-wide zoonotic potential of rat hepatitis E virus.
    J Hepatol. 2025 Jul 14:S0168-8278(25)02339-6. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
43. BJORNSSON ES, Hirschfield GM
    The role of liver biopsy in diagnosing patients with autoimmune hepatitis- it can be acceptable to skip!
    J Hepatol. 2025 Jul 1:S0168-8278(25)02315-3. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    June 2025
44. CHEN Z, Liu L, Situ J, Li G, et al
    Antibodies elicited by hepatitis E vaccination in humans confer cross-genus protection against rat hepatitis E virus.
    J Hepatol. 2025 Jun 24:S0168-8278(25)02283-4. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
45. MUELLER LJ, Schmidt ML, Ciesek S, Corman VM, et al
    Presence but low detection rate of rat Hepatitis E Virus in patients in Germany 2022-2024.
    J Hepatol. 2025 Jun 5:S0168-8278(25)02256-1. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
46. LIU T, Yang X, Zhang H, Yin X, et al
    Prior Hepatitis E virus (HEV) genotype 1 infection is not protective against rat HEV infection in Mongolian gerbils.
    J Hepatol. 2025 Jun 4:S0168-8278(25)02254-8. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
47. BOZWARD AG, Davies SP, Morris SM, Kayani K, et al
    Cellular interactions in self-directed immune-mediated liver diseases.
    J Hepatol. 2025;82:1110-1124.
    PubMed     Abstract available
    
    
    May 2025
48. LOK J, Cargill Z, Anderson M, Cloherty G, et al
    Re: Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta.
    J Hepatol. 2025 May 28:S0168-8278(25)02257-3. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
49. 
    EASL Clinical Practice Guidelines on the management of autoimmune hepatitis.
    J Hepatol. 2025 May 10:S0168-8278(25)00173-4. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
50. 
    EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.
    J Hepatol. 2025 May 8:S0168-8278(25)00174-6. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
51. SCHWARZ T, Ptok J, Damagnez M, Menne C, et al
    HBV shows different levels of adaptation to HLA class I-associated selection pressure correlating with markers of replication.
    J Hepatol. 2025;82:805-815.
    PubMed     Abstract available
    
    
    April 2025
52. HOUGHTON M
    A rat hepacivirus model to aid hepatitis C viral vaccine development ?
    J Hepatol. 2025 Apr 16:S0168-8278(25)00243-0. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
53. SANDMANN L
    Toward functional cure of hepatitis B: Is combination therapy the key?
    J Hepatol. 2025 Apr 15:S0168-8278(25)00212-0. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
54. FERNANDES FF, Ferreira da Silva PG, Villela Nogueira CA
    Follow-up NIT values rather than their variation predict hepatocellular carcinoma after HCV eradication.
    J Hepatol. 2025 Apr 12:S0168-8278(25)00237-5. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
55. MONTES MG, Caraballo LL, Sousa Martin JM
    REPLY TO "UPDATE IN CLINICAL SCIENCE: AUTOIMMUNE HEPATITIS": USE OF ENTERIC-COATED MYCOPHENOLATE SODIUM AS A THERAPEUTIC OPTION FOR AUTOIMMUNE HEPATITIS.
    J Hepatol. 2025 Apr 9:S0168-8278(25)00228-4. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
56. CORMAN VM, Schwarz T, Steinmann E
    Rat hepatitis E virus: the new kid on the block?
    J Hepatol. 2025 Apr 9:S0168-8278(25)00218-1. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
57. LUHMANN N, Wedemeyer H
    More than 10 years of IFN-free HCV treatment and viral hepatitis elimination: Mission not completed!
    J Hepatol. 2025 Apr 8:S0168-8278(25)00220-X. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
58. BUTI M, Riveiro-Barciela M, Forns X
    Rat Hepatitis E: A Silent Threat or Overestimated Risk?
    J Hepatol. 2025 Apr 2:S0168-8278(25)00217-X. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
59. JIN F, Gridley J, Kumari A, Saeidi A, et al
    Hyperfunctional T cell responses unchecked by regulatory T cells are unable to resolve hepaciviral infection without humoral contribution.
    J Hepatol. 2025;82:604-614.
    PubMed     Abstract available
    
    
    March 2025
60. THORSELIUS CE, Wolfisberg R, Fahnoe U, Scheel TKH, et al
    Norway rat hepacivirus resembles hepatitis C virus in terms of intra-host evolution and escape from neutralizing antibodies.
    J Hepatol. 2025 Mar 15:S0168-8278(25)00163-1. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
61. SANCHEZ-TORRIJOS Y, Fernandez-Alvarez P, Rosales JM, Perez-Estrada C, et al
    Recompensation of decompensated cirrhosis in hepatitis C patients after SVR: Prognostic implications.
    J Hepatol. 2025 Mar 6:S0168-8278(25)00153-9. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    February 2025
62. HUANG SC, Su TH
    Divergent Roles of MASLD Components in Chronic Hepatitis B: A Double-Edged Sword.
    J Hepatol. 2025 Feb 28:S0168-8278(25)00144-8. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
63. CABALLERO-GOMEZ J, Casares-Jimenez M, Gallo-Marin M, Pereira-Pardo S, et al
    Rat hepatitis E virus as an aetiological agent of acute hepatitis of unknown origin.
    J Hepatol. 2025 Feb 26:S0168-8278(25)00136-9. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
64. NAHON P, Lusivika-Nzinga C, Merle P, Zoulim F, et al
    Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis.
    J Hepatol. 2025 Feb 26:S0168-8278(25)00084-4. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
65. WANG J, Zhang S, Zhu C, Wu C, et al
    Treatment coverage of the 2024 updated WHO guidelines for patients with chronic hepatitis B.
    J Hepatol. 2025 Feb 8:S0168-8278(25)00077-7. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
66. LAI JC, Cai J, Yip TC
    Reply to: "Evaluating Fracture Risk with TDF in Elderly Hepatitis B Patients: A Korean Perspective".
    J Hepatol. 2025 Feb 8:S0168-8278(25)00076-5. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
67. RAZAVI HA, Waked I, Qureshi H, Kondili LA, et al
    Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies.
    J Hepatol. 2025 Feb 4:S0168-8278(25)00020-0. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
68. LI F, Qu L, Liu Y, Wu X, et al
    PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial.
    J Hepatol. 2025;82:211-221.
    PubMed     Abstract available
    
    
    
69. HAN Y, Tang J, Hu P, Ren H, et al
    Metabolic dysfunction-associated steatotic liver disease may increase intrahepatic interferon gene signatures in patients with chronic hepatitis B.
    J Hepatol. 2025 Feb 1:S0168-8278(25)00073-X. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    January 2025
70. WANG J, Zhang S, Zhu C, Wu C, et al
    Increased HBsAg loss in HBeAg-negative patients with chronic hepatitis B and concurrent MASLD.
    J Hepatol. 2025 Jan 29:S0168-8278(25)00059-5. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
71. HENEGHAN MA, Lohse AW
    Update in Clinical Science: Autoimmune Hepatitis.
    J Hepatol. 2025 Jan 24:S0168-8278(24)02832-0. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
72. SANDMANN L
    Antiviral treatment of chronic hepatitis D virus infection: To combine or not to combine?
    J Hepatol. 2025 Jan 20:S0168-8278(24)02820-4. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
73. DEGASPERI E, Anolli MP, Jachs M, Reiberger T, et al
    Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis.
    J Hepatol. 2025 Jan 8:S0168-8278(25)00001-7. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    December 2024
74. WAN-HIN HUI R, Mak LY, Yuen MF
    Reply to: "ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative hepatitis B patients with Peg-IFNalpha based therapy".
    J Hepatol. 2024 Dec 24:S0168-8278(24)02821-6. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
75. SHIN H, Hur MH, Song BG, Park SY, et al
    AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B.
    J Hepatol. 2024 Dec 20:S0168-8278(24)02784-3. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
76. GAO G, Guo J, Yu G, Li GF, et al
    Long-term use of tenofovir disoproxil fumarate and increased fracture risk in elderly patients with chronic hepatitis B: A Sensitivity Analysis Quantifying Effect of Unmeasured Confounding factors on Observational Associations.
    J Hepatol. 2024 Dec 17:S0168-8278(24)02777-6. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
77. WANG C, Tian H, Shang J
    Assessment of methods in E1E2 versus E2 immunogen studies for HCV vaccine research.
    J Hepatol. 2024 Dec 17:S0168-8278(24)02778-8. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
78. HUANG SC, Su TH, Tseng TC, Hsu SJ, et al
    All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease.
    J Hepatol. 2024 Dec 13:S0168-8278(24)02763-6. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
79. DEGASPERI E, Scholtes C, Testoni B, Renteria SU, et al
    Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta.
    J Hepatol. 2024 Dec 9:S0168-8278(24)02759-4. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
80. LAI-HUNG WONG G, Lemoine M
    The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: main changes and potential implications for the next major liver society clinical practice guidelines.
    J Hepatol. 2024 Dec 6:S0168-8278(24)02755-7. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    November 2024
81. DONGELMANS EJ, Janssen HLA
    Reply to "The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients.".
    J Hepatol. 2024 Nov 29:S0168-8278(24)02746-6. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
82. OKAMOTO T, Hatano E
    Reply to: "Could the paediatric acute hepatitis of unknown origin be related to a new autoimmune disease?".
    J Hepatol. 2024 Nov 29:S0168-8278(24)02747-8. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
83. SHIN YE, Kim JY, Yoo JJ, Kim SG, et al
    Evaluating Fracture Risk with TDF in Elderly Hepatitis B Patients: A Korean Perspective.
    J Hepatol. 2024 Nov 20:S0168-8278(24)02722-3. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
84. SHEN M, He S, Yao N, Li R, et al
    Real-world clinical data-driven modelling on the initiation time of antiviral prophylaxis among pregnant women with chronic hepatitis B infection.
    J Hepatol. 2024 Nov 20:S0168-8278(24)02717-X. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
85. CHE-TO LAI J, Wong GL, Tse YK, Hui VW, et al
    Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: a systematic review and meta-analysis.
    J Hepatol. 2024 Nov 20:S0168-8278(24)02718-1. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
86. LIU Y, Wei Y, Chen X, Huang S, et al
    Genetic study of intrahepatic cholestasis of pregnancy in Chinese women unveils East Asian etiology linked to historic HBV epidemic.
    J Hepatol. 2024 Nov 13:S0168-8278(24)02708-9. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
87. HUR MH, Lee JH
    Reply to "A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?".
    J Hepatol. 2024 Nov 8:S0168-8278(24)02700-4. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
88. MON HC, Huang YH
    Reply to "Immune checkpoint inhibitor therapy for functional cure of hepatitis B in cancer patients: a promising strategy?" and "Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B".
    J Hepatol. 2024 Nov 8:S0168-8278(24)02701-6. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
89. HUI RW, Mak LY, Yuen MF
    Reply to: "Community health strategies for chronic hepatitis B: Advancing care with the ALT/qHBsAg ratio".
    J Hepatol. 2024 Nov 6:S0168-8278(24)02657-6. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
90. BAHCECI D, Hameed B, Gill RM
    Granulomatous hepatitis, a mystery solved.
    J Hepatol. 2024;81:e215-e217.
    PubMed    
    
    
    
91. TONIUTTO P, Falleti E, Cmet S, Cussigh A, et al
    Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide.
    J Hepatol. 2024;81:819-826.
    PubMed     Abstract available
    
    
    October 2024
92. OSMANI Z, Brouwer WP, Grashof DGB, Lim Y, et al
    Metabolic dysfunction-associated steatohepatitis reduces interferon and macrophage liver gene signatures in patients with chronic hepatitis B.
    J Hepatol. 2024 Oct 26:S0168-8278(24)02653-9. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
93. LIU YC, Liaw YF
    The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients.
    J Hepatol. 2024 Oct 18:S0168-8278(24)02638-2. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
94. CHEUK-FUNG YIP T, Peng N, Che-To Lai J
    Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B - Reply to Di et al. and Huang et al.
    J Hepatol. 2024 Oct 16:S0168-8278(24)02633-3. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
95. WANG J, Zhang Q, Zhang S, Wu C, et al
    ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative hepatitis B patients with Peg-IFN-alpha-based therapy.
    J Hepatol. 2024 Oct 16:S0168-8278(24)02628-X. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
96. XIAO G, Ren H
    Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B.
    J Hepatol. 2024 Oct 16:S0168-8278(24)02630-8. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
97. MARTINEZ-LASO J, Cervera I, Munoz M, Casas I, et al
    Could the paediatric acute hepatitis of unknown origin be related to a new autoimmune disease?
    J Hepatol. 2024 Oct 15:S0168-8278(24)02626-6. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
98. SLOOTER CD, Stoelinga AEC, Snijders RJALM
    Reply to: Obtaining first-line induction in autoimmune hepatitis: aren't we underestimating prednisolone?
    J Hepatol. 2024 Oct 4:S0168-8278(24)02580-7. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
99. LIU CH, Cheng PN, Fang YJ, Chen CY, et al
    Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection.
    J Hepatol. 2024 Oct 3:S0168-8278(24)02578-9. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
100. PAPATHEODORIDI M, De Ledinghen V, Lupsor-Platon M, Bronte F, et al
     Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms.
     J Hepatol. 2024;81:590-599.
     PubMed     Abstract available
     
     
     
101. WEDEMEYER H, Aleman S, Brunetto M, Blank A, et al
     Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.
     J Hepatol. 2024;81:621-629.
     PubMed     Abstract available
     
     
     September 2024
102. CUI Y
     Community Health Strategies for Chronic Hepatitis B: Advancing Care with the ALT/qHBsAg Ratio.
     J Hepatol. 2024 Sep 30:S0168-8278(24)02575-3. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
103. LUO J, Gao B, Li B
     Immune checkpoint inhibitor therapy for functional cure of hepatitis B in cancer patients: a promising strategy?
     J Hepatol. 2024 Sep 27:S0168-8278(24)02571-6. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
104. LIN H, Cheuk-Fung Yip T, Lee HW, Meng X, et al
     AI-Safe-C Score: Assessing Liver-Related Event Risks in Non-Cirrhotic Patients after Successful Direct-Acting Antiviral Treatment.
     J Hepatol. 2024 Sep 20:S0168-8278(24)02560-1. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
105. XIAO G, Ren H
     A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?
     J Hepatol. 2024 Sep 19:S0168-8278(24)02556-X. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
106. CHUNG CY, Wang SH, Yeh SH, Chen PJ, et al
     Reply to: Hepatitis B Virus spliced 1 RNA, a key factor for viral expression.
     J Hepatol. 2024 Sep 10:S0168-8278(24)02545-5. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
107. WU JL, Luo JY, Jiang ZB
     Association between antiviral treatments and fracture in elderly patients with HBV needs further evaluation.
     J Hepatol. 2024;81:e108-e109.
     PubMed    
     
     
     August 2024
108. DONGELMANS EJ, Hirode G, Hansen BE, Chen CH, et al
     Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study).
     J Hepatol. 2024 Aug 31:S0168-8278(24)02493-0. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
109. KUDARAVALLI S, Henry L, Nguyen MH
     Integrating Strategic, Equity, and Socioeconomic Perspectives: A Holistic Approach to Advancing Hepatitis B Management and Outcomes.
     J Hepatol. 2024 Aug 30:S0168-8278(24)02491-7. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
110. HUR MH, Yip TC, Kim SU, Lee HW, et al
     A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B.
     J Hepatol. 2024 Aug 30:S0168-8278(24)02494-2. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
111. BUTI M, Heo J, Tanaka Y, Andreone P, et al
     Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B.
     J Hepatol. 2024 Aug 28:S0168-8278(24)02488-7. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
112. KIM SY, Shin EC
     Reply to: "Regulatory T cells dynamics during and after chronic hepatitis C treatment".
     J Hepatol. 2024 Aug 19:S0168-8278(24)02476-0. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
113. CUI A, Chung RT, Alatrakchi N
     Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance - Reply.
     J Hepatol. 2024 Aug 19:S0168-8278(24)02474-7. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     July 2024
114. LOEFFEN EAH, Verkade HJ, van Rheenen PF
     Obtaining first-line induction in autoimmune hepatitis: aren't we underestimating prednisolone?
     J Hepatol. 2024 Jul 30:S0168-8278(24)02427-9. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
115. WANG Y, Guo X, Yuan Y
     Addressing Bias and Improving Research on Gender and Racial Disparities in Hepatitis B Assessment and Treatment.
     J Hepatol. 2024 Jul 30:S0168-8278(24)02428-0. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
116. VENZIN V, Beccaria CG, Andreata F, Fumagalli V, et al
     Intrahepatic immunity to hepatitis B virus.
     J Hepatol. 2024 Jul 30:S0168-8278(24)00364-7. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
117. MON HC, Lee PC, Hung YP, Hung YW, et al
     Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy.
     J Hepatol. 2024 Jul 29:S0168-8278(24)02425-5. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
118. DI J, Song L, Xiang C
     Synergy between public health policy and clinicians plays a key role in reducing fracture risk in patients with viral hepatitis.
     J Hepatol. 2024 Jul 27:S0168-8278(24)02431-0. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
119. SOLIMAN R, Hassan A, Shiha G
     Regulatory T Cells dynamics during and after Chronic Hepatitis C treatment.
     J Hepatol. 2024 Jul 20:S0168-8278(24)02417-6. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
120. RUI F, Ni W, Shi J, Xie Q, et al
     Superior Diagnostic Efficacy of AGILE 3+ Score for Diagnosing Advanced Fibrosis in Chronic Hepatitis B patients with Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease.
     J Hepatol. 2024 Jul 20:S0168-8278(24)02416-4. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
121. BUTI M, Wedemeyer H, Aleman S, Chulanov V, et al
     Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the Phase III MYR301 trial of bulevirtide.
     J Hepatol. 2024 Jul 13:S0168-8278(24)02337-7. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
122. MINAMI T, Fujishiro M, Tateishi R
     Reply to: "Validation of SMART Model for HCC Risk stratification in genotype -4 HCV Patients following SVR and its comparison with GES score".
     J Hepatol. 2024 Jul 9:S0168-8278(24)02361-4. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
123. ZHANG JW, Lai RM, Wang LF, Wang SL, et al
     Varied immune responses of HBV-specific B cells in patients undergoing pegylated interferon-alpha treatment for chronic hepatitis B.
     J Hepatol. 2024 Jul 9:S0168-8278(24)02338-9. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
124. KUNDU J, Le HT, Logan M, Hockman D, et al
     Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone.
     J Hepatol. 2024 Jul 8:S0168-8278(24)02335-3. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
125. TAK WY, Chuang WL, Chen CY, Tseng KC, et al
     Phase 1b/2a randomized study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with chronic hepatitis B.
     J Hepatol. 2024 Jul 5:S0168-8278(24)02333-X. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
126. ZOULIM F, Chen PJ, Dandri M, Kennedy P, et al
     Hepatitis B Virus DNA integration: Implications for diagnostics, therapy, and outcome.
     J Hepatol. 2024 Jul 4:S0168-8278(24)02343-2. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
127. KUDARAVALLI S, Huang DQ, Yeh ML, Trinh L, et al
     Sex and ethnic disparities in hepatitis B evaluation and treatment across the world.
     J Hepatol. 2024;81:33-41.
     PubMed     Abstract available
     
     
     
128. RICCO G, Brunetto MR
     Reply to: "Increase in HDV replication during steroid therapy - potential implications for testing and treatment strategies".
     J Hepatol. 2024;81:e51-e53.
     PubMed    
     
     
     
129. GHANY MG, Buti M, Lampertico P, Lee HM, et al
     Reply to: "Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: Considerations for new and existing therapies".
     J Hepatol. 2024;81:e26-e27.
     PubMed    
     
     
     
130. ANDERSON M, Holzmayer V, Stec M, Cloherty G, et al
     Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: Considerations for new and existing therapies.
     J Hepatol. 2024;81:e24-e25.
     PubMed    
     
     
     
131. PATMORE LA, van der Eijk AA, Janssen HLA, de Man RA, et al
     Increase in HDV replication during steroid therapy - potential implications for testing and treatment strategies.
     J Hepatol. 2024;81:e49-e50.
     PubMed    
     
     
     
132. YU H, Ren J, Deng H, Li L, et al
     Neuropilin-1 is a novel host factor modulating the entry of hepatitis B virus.
     J Hepatol. 2024 Jul 1:S0168-8278(24)02339-0. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     June 2024
133. SLOOTER CD, Stoelinga AEC, Snijders RJALM
     Reply: Mycophenolate Mofetil in Autoimmune Hepatitis: Are We Ready for Primetime?
     J Hepatol. 2024 Jun 15:S0168-8278(24)02318-3. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
134. ZHANG H, Huang J, Zhu W, Feng W, et al
     Does long-term use of tenofovir disoproxil fumarate affect fracture risk in patients with chronic hepatitis B?
     J Hepatol. 2024 Jun 13:S0168-8278(24)02308-0. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
135. KIM SY, Koh JY, Lee DH, Kim HD, et al
     Epigenetic scars in regulatory T cells are retained after successful treatment of chronic hepatitis C with direct-acting antivirals.
     J Hepatol. 2024 Jun 13:S0168-8278(24)02317-1. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
136. PATMORE LA, Sonneveld MJ
     Reply 'Exploring hepatocellular carcinoma risks in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe'.
     J Hepatol. 2024 Jun 11:S0168-8278(24)02311-0. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
137. CHUNG CY, Sun CP, Tao MH, Wu HL, et al
     Major HBV splice variant encoding a novel protein important for infection.
     J Hepatol. 2024;80:858-867.
     PubMed     Abstract available
     
     
     
138. XU M, Warner C, Duan X, Cheng Z, et al
     HIV coinfection exacerbates HBV-induced liver fibrogenesis through a HIF-1alpha- and TGF-beta1-dependent pathway.
     J Hepatol. 2024;80:868-881.
     PubMed     Abstract available
     
     
     May 2024
139. REIBERGER T, Lens S, Cabibbo G, Nahon P, et al
     EASL position paper on clinical follow-up after HCV cure.
     J Hepatol. 2024 May 30:S0168-8278(24)00275-7. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
140. MCCOULLOUGH LC, Fareh M, Hu W, Sozzi V, et al
     CRISPR-Cas13b-mediated suppression of hepatitis B virus replication and protein expression.
     J Hepatol. 2024 May 28:S0168-8278(24)00360-X. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
141. ZHANG Y, Zhou Y
     Enhancing Hepatitis B Management: The Role of Political, Economic, and Educational Considerations in Addressing Global Disparities.
     J Hepatol. 2024 May 24:S0168-8278(24)00357-X. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
142. LI H, Guo Q, Guo C
     A Strategic Approach: Three-Tiered Management for Enhancing Global Hepatitis B Outcomes.
     J Hepatol. 2024 May 22:S0168-8278(24)00358-1. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
143. GOMEZ-MORENO A, Guo J, Temple HM, Ploss A, et al
     Formation and transcriptional regulation of hepatitis B virus covalently closed circular DNA.
     J Hepatol. 2024 May 22:S0168-8278(24)00159-4. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
144. CHAPUS F, Giraud G, Huchon P, Roda M, et al
     Helicases DDX5 and DDX17 promote heterogeneity in HBV transcription termination in infected human hepatocytes.
     J Hepatol. 2024 May 21:S0168-8278(24)00351-9. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
145. COLAPIETRO F, Lleo A
     Reply: Incidence And Predictors Of Hepatocellular Carcinoma In Patients With Autoimmune Hepatitis?
     J Hepatol. 2024 May 20:S0168-8278(24)00354-4. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
146. LAI JC, Yip TC, Wong GL
     Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B - Reply to Wu et al.
     J Hepatol. 2024 May 17:S0168-8278(24)00344-1. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
147. WEN Z
     Enhancing the understanding of the risk of incident fracture in entecavir- and TDF-treated elderly patients with chronic hepatitis B (CHB).
     J Hepatol. 2024 May 16:S0168-8278(24)00347-7. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
148. SHIHA G, Mikhail N, Soliman R
     Validation of SMART Model for HCC Risk stratification in genotype -4 HCV Patients following SVR and its comparison with GES score.
     J Hepatol. 2024 May 15:S0168-8278(24)00348-9. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
149. BABLON P, Goy C, Dang HN, Sotty J, et al
     Hepatitis B Virus spliced 1 RNA, a key factor for viral expression.
     J Hepatol. 2024 May 9:S0168-8278(24)00331-3. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
150. YANG F, Fan X, Zhou L, Yang L, et al
     Need for risk stratification in treatment of patients with autoimmune hepatitis.
     J Hepatol. 2024 May 9:S0168-8278(24)00338-6. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
151. VAN OORSCHOT E, Koc OM, Koek GH
     Osteoporosis in hepatitis B patients receiving tenofovir disoproxil fumarate: does fibroblast growth factor 23 play a role?
     J Hepatol. 2024 May 2:S0168-8278(24)00323-4. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
152. QI R, Fu R, Lei X, He J, et al
     Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels.
     J Hepatol. 2024;80:714-729.
     PubMed     Abstract available
     
     
     April 2024
153. HEGARTY R, Hadzic N
     GENOMIC TESTING FOR INBORN ERRORS OF IMMUNITY IN SERONEGATIVE AUTOIMMUNE HEPATITIS OF CHILDHOOD.
     J Hepatol. 2024 Apr 26:S0168-8278(24)00289-7. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
154. TAN MY, Su JH
     Exploring Hepatocellular Carcinoma Risks in Sub-Saharan African and Afro-Surinamese Individuals with Chronic Hepatitis B living in Europe.
     J Hepatol. 2024 Apr 26:S0168-8278(24)00287-3. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
155. KENNEDY MJ, Fernbach S, Scheel TKH
     Animal hepacivirus models for hepatitis C virus immune responses and pathology.
     J Hepatol. 2024 Apr 24:S0168-8278(23)05373-4. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
156. UNDERWOOD AP, Gupta M, Wu BR, Eltahla AA, et al
     B cell characteristics define HCV reinfection outcome.
     J Hepatol. 2024 Apr 9:S0168-8278(24)00271-X. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
157. AGARWAL K, Buti M, van Bommel F, Lampertico P, et al
     JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2.
     J Hepatol. 2024 Apr 5:S0168-8278(24)00231-9. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
158. KONDILI LA, Lazarus JV, Jepsen P, Murray F, et al
     Inequities in primary liver cancer in Europe: The state of play.
     J Hepatol. 2024;80:645-660.
     PubMed     Abstract available
     
     
     March 2024
159. BJORNSSON ES, Lucena MI, Andrade RJ
     Reply to the Letter to the Editor: Distinction of Autoimmune Hepatitis from Drug Induced Autoimmune Like Hepatitis: The Answer Lies at the Interface.
     J Hepatol. 2024 Mar 28:S0168-8278(24)00221-6. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
160. SNIJDERS RJALM, Stoelinga AEC, van Hoek B, Drenth JPH, et al
     Prednisolone with azathioprine or mycophenolate mofetil as first-line therapy in autoimmune hepatitis: insights from a randomized controlled trial.
     J Hepatol. 2024 Mar 28:S0168-8278(24)00222-8. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
161. HIN-MAN LEUNG R, Wan-Hin Hui R, Mak LY, Mao X, et al
     ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B.
     J Hepatol. 2024 Mar 23:S0168-8278(24)00204-6. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
162. PASTA A, Pieri G, Plaz Torres MC, Trevisani F, et al
     Hepatocellular carcinoma in patients with Autoimmune Hepatitis.
     J Hepatol. 2024 Mar 23:S0168-8278(24)00208-3. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
163. PLAGIANNAKOS CG, Hirschfield GM, Lytvyak E, Roberts SB, et al
     Treatment response and clinical event-free survival in autoimmune hepatitis: a Canadian multicentre cohort study.
     J Hepatol. 2024 Mar 23:S0168-8278(24)00205-8. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
164. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
     Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.
     J Hepatol. 2024 Mar 21:S0168-8278(24)00198-3. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
165. BISWAS S, Shalimar
     Mycophenolate Mofetil in Autoimmune Hepatitis: Are We Ready for Primetime?
     J Hepatol. 2024 Mar 20:S0168-8278(24)00201-0. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
166. TONNERRE P, Baumert TF
     Unraveling the liver antiviral immunity in functional cure of chronic hepatitis B using scRNASeq.
     J Hepatol. 2024 Mar 19:S0168-8278(24)00200-9. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
167. THURSZ M, Mathurin P
     Targeting IL-1 in severe alcohol-related hepatitis; how many frogs will we need to kiss to find an effective therapy?
     J Hepatol. 2024 Mar 16:S0168-8278(24)00163-6. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
168. JACHS M, Sandmann L, Hartl L, Tergast T, et al
     Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
     J Hepatol. 2024 Mar 11:S0168-8278(24)00156-9. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
169. SEITZ S, Bartenschlager R
     Cutting edges in the hepatitis B virus genome: How RNA splicing is involved in modulating virus ultrastructure to promote infection.
     J Hepatol. 2024 Mar 7:S0168-8278(24)00148-X. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
170. SIMSEK C, Wahlin S, Efe C
     Autoimmune Hepatitis: Mycophenolate mofetil versus azathioprine as first line therapy.
     J Hepatol. 2024 Mar 6:S0168-8278(24)00142-9. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
171. SHEEHAN Y, Grebely J, Lloyd AR
     Reply to: " 'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison - some issues".
     J Hepatol. 2024;80:e107-e108.
     PubMed    
     
     
     February 2024
172. NARMADA BC, Khakpoor A, Shirgaonkar N, Narayanan S, et al
     Single cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity.
     J Hepatol. 2024 Feb 27:S0168-8278(24)00137-5. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
173. ALRIC L
     Should MMF treatment be the first-line therapy in autoimmune hepatitis?
     J Hepatol. 2024 Feb 23:S0168-8278(24)00134-X. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
174. TIWARI A, Khanikar D, Rathod SG
     "Autoimmune Hepatitis: Azathioprine or Mycophenolate Mofetil for inducing remission?".
     J Hepatol. 2024 Feb 23:S0168-8278(24)00132-6. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
175. BIALLAS R, Zimmermann R, Dudareva S
     Reply to: Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany.
     J Hepatol. 2024 Feb 23:S0168-8278(24)00133-8. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
176. YANG H, Jang JW
     Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!'.
     J Hepatol. 2024 Feb 10:S0168-8278(24)00123-5. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
177. GAWRIEH S, Dasarathy S, Tu W, Kamath PS, et al
     Randomized-controlled trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis.
     J Hepatol. 2024 Feb 9:S0168-8278(24)00109-0. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
178. ALLWEISS L, Volmari A, Suri V, Wallin JJ, et al
     Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
     J Hepatol. 2024 Feb 8:S0168-8278(24)00114-4. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
179. LIU C, Guo C, Liu K
     Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance.
     J Hepatol. 2024 Feb 6:S0168-8278(24)00121-1. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
180. HEUSCHKEL MJ, Bach C, Meiss-Heydmann L, Gerges E, et al
     JAK1 promotes HDV replication and is a potential target for antiviral therapy.
     J Hepatol. 2024;80:220-231.
     PubMed     Abstract available
     
     
     
181. HIRSCHFIELD GM, Lohse AW
     Editorial: Treating Autoimmune Hepatitis - more science, more progress, better therapy.
     J Hepatol. 2024 Feb 1:S0168-8278(24)00098-9. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
182. ALKASHASH A, Zhang X, Vuppalanchi R, Lammert C, et al
     Distinction of Autoimmune Hepatitis from Drug Induced Autoimmune Like Hepatitis: The Answer Lies at the Interface.
     J Hepatol. 2024 Feb 1:S0168-8278(24)00100-4. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     January 2024
183. FAN X, Yang F, Zhou L, Yang L, et al
     Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis.
     J Hepatol. 2024 Jan 31:S0168-8278(24)00097-7. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
184. HEO M, Norton BL, Pericot-Valverde I, Mehta SH, et al
     Optimal Hepatitis C Treatment Adherence Patterns and Sustained Virologic Response. among People Who Inject Drugs: The HERO Study.
     J Hepatol. 2024 Jan 17:S0168-8278(23)05374-6. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
185. HACHICHA-MAALEJ N, Collins IJ, Ades AE, Scott K, et al
     Corrigendum to "Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine" [J Hepatol (2023) 937-946].
     J Hepatol. 2024 Jan 4:S0168-8278(23)05367-9. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
186. THOMPSON LA, Charlton CL
     Evaluation and comparison of risk-based and universal HCV screening programs.
     J Hepatol. 2024 Jan 3:S0168-8278(24)00005-9. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
187. ZHANG Y, Bourgine M, Wan Y, Song J, et al
     Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers.
     J Hepatol. 2024;80:31-40.
     PubMed     Abstract available
     
     
     
188. TROVATO FM, McPhail M
     Reply to: "Dysregulation of the LPC-ATX-LPA axis in autoimmune hepatitis is associated with monocyte activation": Autotaxin upregulation in liver failure and the effect on monocyte phenotype and function is a pan-aetiology phenomenon.
     J Hepatol. 2024;80:e16-e18.
     PubMed    
     
     
     December 2023
189. CSERNALABICS B, Marinescu MS, Maurer L, Kelsch L, et al
     Efficient formation and maintenance of humoral and CD4 T cell immunity targeting the viral capsid in acute-resolving hepatitis E infection.
     J Hepatol. 2023 Dec 26:S0168-8278(23)05370-9. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
190. VAN BOMMEL F, Berg T
     Response to: A comment on "A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.".
     J Hepatol. 2023 Dec 16:S0168-8278(23)05356-4. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
191. CHE-TO LAI J, Lai-Hung Wong G, Wai-Sun Wong V, Cheuk-Fung Yip T, et al
     Unmet need in screening for hepatitis D virus: time to take action.
     J Hepatol. 2023 Dec 16:S0168-8278(23)05360-6. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
192. SNIJDERS RJ, Stoelinga AE, Gevers TJ, Pape S, et al
     An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis.
     J Hepatol. 2023 Dec 13:S0168-8278(23)05309-6. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
193. CHEUK-FUNG YIP T, Che-To Lai J, Yam TF, Tse YK, et al
     Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B.
     J Hepatol. 2023 Dec 13:S0168-8278(23)05354-0. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     November 2023
194. COLASANTI O, Burm R, Huang HE, Riedl T, et al
     Corrigendum to "Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation" [J Hepatol (2023) 645-656].
     J Hepatol. 2023 Nov 30:S0168-8278(23)05282-0. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
195. 
     The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories.
     J Hepatol. 2023 Nov 27:S0168-8278(23)05285-6. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
196. BALAGOPAL A, Thomas DL
     Genomics on the road to functional cure of hepatitis B.
     J Hepatol. 2023 Nov 18:S0168-8278(23)05276-5. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
197. HUPPE D, Wedemeyer H, Cornberg M
     Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany.
     J Hepatol. 2023 Nov 3:S0168-8278(23)05234-0. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
198. GANE EJ, Kim W, Lim TH, Tangkijvanich P, et al
     First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection.
     J Hepatol. 2023;79:1139-1149.
     PubMed     Abstract available
     
     
     
199. ZHANG Y, Tan W, Wang X, Zheng X, et al
     Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes.
     J Hepatol. 2023;79:1159-1171.
     PubMed     Abstract available
     
     
     
200. LEMPP FA, Volz T, Cameroni E, Benigni F, et al
     Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice.
     J Hepatol. 2023;79:1129-1138.
     PubMed     Abstract available
     
     
     October 2023
201. PATMORE LA, van Eekhout KMA, Buti M, Koc OM, et al
     Hepatocellular carcinoma risk in Sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
     J Hepatol. 2023 Oct 26:S0168-8278(23)05219-4. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
202. MURRAY SM, Pose E, Wittner M, Londono MC, et al
     Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and in liver transplant recipients.
     J Hepatol. 2023 Oct 18:S0168-8278(23)05174-7. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
203. GUAN G, Zhang T, Ning J, Tao C, et al
     Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-alpha-treated patients with chronic hepatitis B.
     J Hepatol. 2023 Oct 17:S0168-8278(23)05175-9. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
204. PANDURANGI S, Malik A, Owens J, Valencia CA, et al
     Deleterious variants in TNFAIP3 are associated with type II and seronegative Pediatric autoimmune hepatitis.
     J Hepatol. 2023 Oct 9:S0168-8278(23)05156-5. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
205. GRONBAEK L, Gronbaek H
     Editorial: Hepatocellular carcinoma in autoimmune hepatitis remains rare.
     J Hepatol. 2023 Oct 9:S0168-8278(23)05159-0. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
206. COLAPIETRO F, Maisonneuve P, Lytvyak E, Beuers U, et al
     Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
     J Hepatol. 2023 Oct 4:S0168-8278(23)05095-X. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
207. LU W
     A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!
     J Hepatol. 2023 Oct 3:S0168-8278(23)05142-5. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     September 2023
208. CHUN HS, Papatheodoridis GV, Lee M, Lee HA, et al
     PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
     J Hepatol. 2023 Sep 19:S0168-8278(23)05096-1. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     June 2023
209. MINAMI T, Sato M, Toyoda H, Yasuda S, et al
     Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.
     J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
210. FAN R, Chen L, Zhao S, Yang H, et al
     Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
     J Hepatol. 2023 Jun 9:S0168-8278(23)00416-6. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     March 2023
211. GANE EJ, Dunbar PR, Brooks AE, Zhang F, et al
     Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression.
     J Hepatol. 2023;78:513-523.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum